الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 356 |  |  |
| | | from | 356 | | |
Abstract
Polycystic ovarian syndrome (PCOS) is a widespread female endocrine condition that affects between 8 and 18 percent of the female population, depending on the diagnostic criteria employed (ESHRE and ASRM). PCOS is a complex metabolic, long term condition requiring continuous medical care beyond multifactorial risk reduction strategies. The major factors of PCOS, hyperandrogenism, ovarian dysfunction, and metabolic abnormalities, all appear to have a synergistic role in the pathogenesis of PCOS (1).
Menstrual irregularity, anovulatory infertility, hyperandrogenism, and obesity are among the symptoms, as are metabolic dysfunctions such as insulin resistance (IR), type 2 diabetes, and dyslipidemia (2). These symptoms can have a significant influence on patients’ quality of life and health. However, because of the disease’s intricacy, the etiology is unknown, and an appropriate therapy has yet to be discovered (3,4). There is an increasing demand for novel treatments for this disorder.